Suppr超能文献

不可切除肝细胞癌:经动脉治疗后的磁共振成像。第一部分。容积功能反应标准的鉴定和验证。

Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

机构信息

Russell H. Morgan Department of Radiology and Radiological Science and Department of Surgery and Oncology, The Johns Hopkins Hospital, 600 N Wolfe St, MRI 143, Baltimore, MD 21287, USA.

出版信息

Radiology. 2013 Aug;268(2):420-30. doi: 10.1148/radiol.13122307. Epub 2013 Apr 24.

Abstract

PURPOSE

To identify and validate the optimal thresholds for volumetric functional MR imaging response criteria to predict overall survival after intraarterial treatment (IAT) in patients with unresectable hepatocellular carcinoma (HCC).

MATERIALS AND METHODS

Institutional review board approval and waiver of informed consent were obtained. A total of 143 patients who had undergone MR imaging before and 3-4 weeks after the first cycle of IAT were included. MR imaging analysis of one representative HCC index lesion was performed with proprietary software after initial treatment. Subjects were randomly divided into training (n = 114 [79.7%]) and validation (n = 29 [20.3%]) data sets. Uni- and multivariate Cox models were used to determine the best cutoffs, as well as survival differences, between response groups in the validation data set.

RESULTS

Optimal cutoffs in the training data set were 23% increase in apparent diffusion coefficient (ADC) and 65% decrease in volumetric enhancement in the portal venous phase (VE). Subsequently, 25% increase in ADC and 65% decrease in VE were used to stratify patients in the validation data set. Comparison of ADC responders (n = 12 [58.6%]) with nonresponders (n = 17 [34.5%]) showed significant differences in survival (25th percentile survival, 11.2 vs 4.9 months, respectively; P = .008), as did VE responders (n = 9 [31.0%]) compared with nonresponders (n = 20 [69.0%]; 25th percentile survival, 11.5 vs 5.1 months, respectively; P = .01). Stratification of patients with a combination of the criteria resulted in significant differences in survival between patients with lesions that fulfilled both criteria (n = 6 [20.7%]; too few cases to determine 25th percentile), one criterion (n = 9 [31.0%]; 25th percentile survival, 6.0 months), and neither criterion (n = 14 [48.3%]; 25th percentile survival, 5.1 months; P = .01). The association between the two criteria and overall survival remained significant in a multivariate analysis that included age, sex, Barcelona Clinic for Liver Cancer stage, and number of follow-up treatments.

CONCLUSION

After IAT for unresectable HCC, patients can be stratified into significantly different survival categories based on responder versus nonresponder status according to MR imaging ADC and VE cutoffs.

摘要

目的

确定并验证容积功能磁共振成像(fMRI)反应标准的最佳阈值,以预测不可切除肝细胞癌(HCC)患者接受动脉内治疗(IAT)后的总生存率。

材料与方法

本研究获得了机构审查委员会的批准和知情同意豁免。共纳入了 143 例在 IAT 第一周期前和 3-4 周后接受 MRI 检查的患者。在初始治疗后,使用专有的软件对一个代表性的 HCC 指数病变进行 MRI 分析。将受试者随机分为训练(n=114 [79.7%])和验证(n=29 [20.3%])数据集。使用单变量和多变量 Cox 模型来确定验证数据集中反应组之间的最佳截止值以及生存差异。

结果

在训练数据集中,最佳截止值为表观扩散系数(ADC)增加 23%和门静脉期容积增强(VE)减少 65%。随后,将 ADC 增加 25%和 VE 减少 65%用于对验证数据集中的患者进行分层。与非应答者(n=17 [34.5%])相比,ADC 应答者(n=12 [58.6%])的生存差异有统计学意义(25%生存百分位,分别为 11.2 个月和 4.9 个月;P=.008),VE 应答者(n=9 [31.0%])与非应答者(n=20 [69.0%])的生存差异也有统计学意义(25%生存百分位,分别为 11.5 个月和 5.1 个月;P=.01)。满足两种标准的患者(n=6 [20.7%];病例太少,无法确定 25%生存百分位)、仅满足一种标准的患者(n=9 [31.0%];25%生存百分位为 6.0 个月)和两种标准均不满足的患者(n=14 [48.3%];25%生存百分位为 5.1 个月)之间的生存差异有统计学意义(P=.01)。在包括年龄、性别、巴塞罗那临床肝癌分期和随访治疗次数在内的多变量分析中,两种标准与总生存率的关联仍然显著。

结论

在不可切除 HCC 患者接受 IAT 后,根据 MRI ADC 和 VE 截止值,患者可以分为应答者和非应答者,这两组患者的生存情况有显著差异。

相似文献

引用本文的文献

9
Functional imaging of hepatocellular carcinoma.肝细胞癌的功能成像
Hepat Oncol. 2016 Apr;3(2):137-153. doi: 10.2217/hep-2015-0005. Epub 2016 Mar 29.
10
New concepts in embolotherapy of HCC.肝癌栓塞治疗的新概念。
Med Oncol. 2017 Apr;34(4):58. doi: 10.1007/s12032-017-0917-2. Epub 2017 Mar 16.

本文引用的文献

7
Cancer statistics, 2010.癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
10
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.改良版 RECIST(mRECIST)用于肝细胞癌的评估。
Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验